Company profile ADAP

Adaptimmune Therapeutics Plc
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in ...2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page. Show More
Quarter analysis & expected interestLast update: February 08 2024 12:57:21.

After 39 days of this quarter the interest is at 162.0. Based on that we can calculate that during remaining 52 days it will total up to 378.0.
Adaptimmune expected interest is significantly higher compared to previous quarter (+53.7%) and same quarter last year (+83.5%).

YearQ1Q2Q3Q4
2019145
281
93.8% QoQ
249
-11.4% QoQ
191
-23.3% QoQ
2020 310
113.8% YoY 62.3% QoQ
443
57.7% YoY 42.9% QoQ
250
0.4% YoY -43.6% QoQ
220
15.2% YoY -12.0% QoQ
2021 215
-30.6% YoY -2.3% QoQ
166
-62.5% YoY -22.8% QoQ
285
14.0% YoY 71.7% QoQ
173
-21.4% YoY -39.3% QoQ
2022 187
-13.0% YoY 8.1% QoQ
224
34.9% YoY 19.8% QoQ
160
-43.9% YoY -28.6% QoQ
260
50.3% YoY 62.5% QoQ
2023 206
10.2% YoY -20.8% QoQ
151
-32.6% YoY -26.7% QoQ
199
24.4% YoY 31.8% QoQ
246
-5.4% YoY 23.6% QoQ
2024 162
-21.4% YoY -34.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Adaptimmune search interestLast update: February 08 2024 12:57:20.
Correlation coefficient between keyword and revenue is -0.18
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:57:23.

The average 5 years interest of Adaptimmune was 18.1 per week.
The last year interest of Adaptimmune compared to the last 5 years has changed by -4.25%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -13.87%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:57:29.

After 39 days of this quarter the interest is at 85.0. Based on that we can calculate that during remaining 52 days it will total up to 198.0.
Adaptimmune Therapeutics expected interest is significantly higher compared to previous quarter (+94.1%) and same quarter last year (+83.3%).

YearQ1Q2Q3Q4
20190
198
inf% QoQ
104
-47.5% QoQ
231
122.1% QoQ
2020 156
inf% YoY -32.5% QoQ
323
63.1% YoY 107.1% QoQ
192
84.6% YoY -40.6% QoQ
223
-3.5% YoY 16.1% QoQ
2021 123
-21.2% YoY -44.8% QoQ
88
-72.8% YoY -28.5% QoQ
165
-14.1% YoY 87.5% QoQ
24
-89.2% YoY -85.5% QoQ
2022 106
-13.8% YoY 341.7% QoQ
197
123.9% YoY 85.8% QoQ
93
-43.6% YoY -52.8% QoQ
57
137.5% YoY -38.7% QoQ
2023 108
1.9% YoY 89.5% QoQ
56
-71.6% YoY -48.1% QoQ
139
49.5% YoY 148.2% QoQ
102
78.9% YoY -26.6% QoQ
2024 85
-21.3% YoY -16.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Adaptimmune Therapeutics search interestLast update: February 08 2024 12:57:28.
Correlation coefficient between keyword and revenue is -0.24
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:57:31.

The average 5 years interest of Adaptimmune Therapeutics was 10.61 per week.
The last year interest of Adaptimmune Therapeutics compared to the last 5 years has changed by -23.0%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -31.34%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune cancer therapy to provide analysis

Correlation between past revenue and Adaptimmune cancer therapy search interest

There is not enough data for Adaptimmune cancer therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune cancer therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune clinical trials to provide analysis

Correlation between past revenue and Adaptimmune clinical trials search interest

There is not enough data for Adaptimmune clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune Research to provide analysis

Correlation between past revenue and Adaptimmune Research search interest

There is not enough data for Adaptimmune Research to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune Research to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune careers to provide analysis

Correlation between past revenue and Adaptimmune careers search interest

There is not enough data for Adaptimmune careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune reviews to provide analysis

Correlation between past revenue and Adaptimmune reviews search interest

There is not enough data for Adaptimmune reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune UK to provide analysis

Correlation between past revenue and Adaptimmune UK search interest

There is not enough data for Adaptimmune UK to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune UK to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Adaptimmune US to provide analysis

Correlation between past revenue and Adaptimmune US search interest

There is not enough data for Adaptimmune US to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Adaptimmune US to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:57:38.

After 39 days of this quarter the interest is at 114.0. Based on that we can calculate that during remaining 52 days it will total up to 266.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019120
317
164.2% QoQ
276
-12.9% QoQ
228
-17.4% QoQ
2020 334
178.3% YoY 46.5% QoQ
335
5.7% YoY 0.3% QoQ
297
7.6% YoY -11.3% QoQ
273
19.7% YoY -8.1% QoQ
2021 208
-37.7% YoY -23.8% QoQ
240
-28.4% YoY 15.4% QoQ
220
-25.9% YoY -8.3% QoQ
225
-17.6% YoY 2.3% QoQ
2022 259
24.5% YoY 15.1% QoQ
326
35.8% YoY 25.9% QoQ
202
-8.2% YoY -38.0% QoQ
275
22.2% YoY 36.1% QoQ
2023 316
22.0% YoY 14.9% QoQ
279
-14.4% YoY -11.7% QoQ
323
59.9% YoY 15.8% QoQ
219
-20.4% YoY -32.2% QoQ
2024 114
-63.9% YoY -47.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Adaptimmune -stock -company search interestLast update: February 08 2024 12:57:38.
Correlation coefficient between keyword and revenue is 0.23
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:57:40.

The average 5 years interest of Adaptimmune -stock -company was 20.64 per week.
The last year interest of Adaptimmune -stock -company compared to the last 5 years has changed by 7.17%.
The interest for Adaptimmune -stock -company is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 2.17%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ADAP
Earnings date: 2024-03-04 After close
Company name: Adaptimmune Therapeutics Plc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-10-20T07:50:19-04:00

SEC
8-K Form - Current report, items 3.01, 7.01, and 9.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-10-08T21:00:14-04:00

SEC
3 Form - Initial statement of beneficial ownership of securities - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

2025-09-26T16:30:18-04:00

SEC
8-K Form - Current report, item 3.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-09-12T16:27:38-04:00

SEC
8-K Form - Current report, item 3.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-09-08T16:05:16-04:00

SEC
8-K Form - Current report, items 5.02 and 9.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-09-03T17:00:21-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

2025-09-02T08:00:30-04:00

SEC
144 Form - Report of proposed sale of securities - Adaptimmune Therapeutics PLC (0001621227) (Subject)

2025-08-29T18:25:42-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

2025-08-29T18:24:35-04:00

SEC
144 Form - Report of proposed sale of securities - Adaptimmune Therapeutics PLC (0001621227) (Subject)

2025-08-29T16:30:45-04:00

SEC
8-K Form - Current report, items 5.02 and 9.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-08-07T16:30:12-04:00

SEC
8-K Form - Current report, items 5.02 and 9.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-07-31T17:02:43-04:00

SEC
8-K Form - Current report, items 1.02, 2.01, and 9.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)

2025-07-30T18:20:32-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

2025-07-29T11:47:18Z

Analyst Upgrades
HC Wainwright & Co. Downgrades Adaptimmune Therapeutics to Neutral

2025-07-28T07:37:31-04:00

SEC
8-K Form - Current report, items 1.01, 2.05, 5.02, 7.01, and 9.01 - Adaptimmune Therapeutics PLC (0001621227) (Filer)